Aziz Mottiwala - 08 Nov 2021 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: Chief Commercial Officer
Signature: /s/ Leonard M. Greenstein, Attorney-in-Fact
Issuer symbol: TARS
Transactions as of: 08 Nov 2021
Net transactions value: -$53,100
Form type: 4
Filing time: 10 Nov 2021, 17:29:55 UTC
Previous filing: 08 Nov 2021
Next filing: 11 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TARS	Common Stock	Sale	$53,100	-1,889	-3.6%	$28.11	50,203	08 Nov 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2021.
F2	The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $28.00 to $28.56. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2021.

The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $28.00 to $28.56. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.